Relationship between the serum chemokine IP-10 and RANTES levels and Interferon therapeutic early response in patients with chronic hepatitis B
10.3760/cma.j.issn.1008-6706.2012.09.002
- VernacularTitle:干扰素α-2b对慢性乙型肝炎患者血清干扰素诱导蛋白、活性调节蛋白水平的影响
- Author:
Wenli LI
;
Maosheng WU
;
Yubo HUANG
;
Jifen ZHU
;
Xiling LIU
;
Ruirong XU
- Publication Type:Journal Article
- Keywords:
Hepatitis B;
Interferon Alfa-2b
- From:
Chinese Journal of Primary Medicine and Pharmacy
2012;19(9):1283-1285
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between the serum chemokine IP-10 and RANTES levels and Interferon therapeutic early response in patients with chronic hepatitis B(CHB).Methods 50 patients with chronic hepatitis B were chosen into interferon therapy.After 12 weeks,they were devided into three groups:complete response A、partial response B、non response C group.HBV-DNA was detected by PCR;The serum chemokines( IP-10 and RANTES) were measured by Luminex Liquichip technology.Results The base HBV DNA and RANTES levels of three groups weren't significantly different (P ＜0.05) ;The base ALT and IP-10 levels of A group were significantly higher than that in B and C group( P ＜ 0.05).The IP-10、RANTES contents of A group in therapeutic 4th week were significantly lower than that before interferon therapy(P ＜ 0.05 );There were no significant differences in B、C group (P ＞0.05) ;The levels changes of IP-10、RANTES、HBV DNA and ALT in therapeutic 12th week were significantly different between the three groups ( P ＜ 0.05 ),The level of ALT in 50 patients has positive correlation with IP-10 level (P ＜ 0.05) ;The level of HBV DNA in 50 patients had positive correlation with RANTES level( P ＜ 0.05 ) ;The base level of IP-10 had positive correlation with the change of HBV-DNA contents in therapeutic 12th week( P ＜0.05 ) ;The change of ALT level in reponse patients in therapeutic 12th week had positive correlation with the change of IP-10 、RANTES levels( P ＜ 0.05 ).Conclusion The decrease of IP-10,RANTES level in CHB patients received 12weeks interferon-α therapy could lead to reduce liver inflammation;The base IP-10 level probably was relevant to the early response in CHB patients received interferon-α therapy.
